Susceptibility testing in Aspergillus species complex.
Clin Microbiol Infect. 2013 Dec 21;
Authors: Lass-Flörl C
Methods for susceptibility testing of Aspergillus are developed and validated by the EUCAST subcommittee on Antifungal Susceptibility Testing. Breakpoints for phenotypic antimicrobial susceptibility testing have been determined by breakpoint committees and as part of regulatory processes for the approval of new drugs. Dosages, pharmacokinetics, resistance mechanisms, MIC distributions, pharmacodynamics and epidemiological cutoff values are used in the breakpoint-setting process. Clinical breakpoints are for everyday use in the clinical laboratory to advise on patient therapy. Resistance in Aspergillus fumigatus has been increasingly reported since standards became available. This article is protected by copyright. All rights reserved.
PMID: 24372722 [PubMed - as supplied by publisher]